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Autoimmune diseases are characterized by an aberrantly activated immune system,
resulting in tissue damage and functional disability in patients. An important
therapeutic goal is to restore the deregulated immunological balance between pro- and
anti-inflammatory T cells. This imbalance is illustrated by elevated levels and activity
of memory Th17 cell populations, such as Th17, Th1/Th17, and Th17.1 cells, in
various autoimmune diseases. These cells are characterized by the chemokine receptor
CCR6, RORC expression and production of IL-17A, IFNγ, and TNFα. Using rheumatoid
arthritis (RA) as a model of autoimmune disease, we here demonstrate that pro-
inflammatory memory CCR6+ Th cells can switch into anti-inflammatory cells with
regulatory capacity using the active vitamin D metabolite 1,25(OH)2D3. Memory CCR6+
Th cells, excluding Tregs, were sorted from healthy controls or treatment-naïve patients
with early rheumatoid arthritis (RA) and cultured with or without 1,25(OH)2D3. Treatment
with 1,25(OH)2D3 inhibited pro-inflammatory cytokines such as IL-17A, IL-17F, IL-22
and IFNγ in memory CCR6+ Th cells from both healthy controls and RA patients. This
was accompanied by induction of anti-inflammatory factors, including IL-10 and CTLA4.
Interestingly, these formerly pathogenic cells suppressed proliferation of autologous
CD3+ T cells similar to classical Tregs. Importantly, the modulated memory cells
still migrated toward inflammatory milieus in vitro, modeled by RA synovial fluid, and
retained their suppressive capacity in this environment. These data show the potential
to reset the pathogenic profile of human memory Th cells into non-pathogenic cells with
regulatory capacity.
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INTRODUCTION
Autoimmune diseases are an increasing health problem in the
Western industrialized countries (1). Even though treatment
has improved in the last decades with the introduction of so-
called “biologicals,” many patients do not respond to or become
resistant to treatment. Also, we are still not able to cure these
disabling diseases (2). In order to achieve better treatment of
the patients, it is crucial to understand the pathogenesis of
autoimmune diseases and how the important players in this
pathogenesis can be modulated.
An important hallmark of many autoimmune diseases is a
disturbed balance between pro- and anti-inflammatory cells,
exemplified by T-helper-17 (Th17) cells and regulatory T cells
(3–5). Pro-inflammatory Th17 cell populations, which are
distinguished by the expression of CCR6 and include Th17,
Th1/Th17, and Th17.1 cells, are elevated and more active in
various autoimmune diseases including RA, systemic lupus
erythematosus, and inflammatory bowel diseases (6–9). On the
other hand, anti-inflammatory regulatory T cells, such as classical
regulatory T cells (Tregs) and type 1 regulatory (Tr1) cells are
reduced in number and functionality in human autoimmune
diseases (10). Furthermore, Th17 cells and IL-17-mediated
signaling are required for the development of experimental
autoimmune diseases such as collagen-induced arthritis
and experimental autoimmune encephalomyelitis, whereas
regulatory T cells protect against experimental autoimmunity
(11–15). Therefore, normalizing the Th17/Treg balance to
suppress the autoimmune response is an important therapeutic
goal in RA (16).
A natural agent that could play a role in the Th17/Treg
balance is vitamin D. Not only are serum vitamin D levels
reduced in patients with autoimmune diseases (17), its active
metabolite 1,25(OH)2D3 is also a potent inhibitor of Th17
pathogenicity (18–23). Furthermore, 1,25(OH)2D3 promotes
Treg differentiation and function (19, 24–26) and suppresses
experimental autoimmunity (27–31).
Interestingly, it was recently shown that IL-17A-producing
cells acquire a regulatory phenotype similar to Tr1 cells during
normal resolution of inflammation, indicating the potential of
pro-inflammatory cells to switch to a regulatory phenotype
(32). Exploiting this process would be extremely relevant to
restore the Th17/Treg balance in human autoimmune disease,
but it is currently unknown if human Th17 cells can also
transdifferentiate into Tregs and how this transition could be
induced. Given its potent effects on Th17 cells and Tregs, we
here studied whether human memory Th17 cell population can
acquire regulatory properties using 1,25(OH)2D3.
MATERIALS AND METHODS
Subjects
Healthy control peripheral blood mononuclear cells (PBMC, n
= 24 in total) were used in most experiments and isolated from
buffy coats obtained from Sanquin Blood Bank (Rotterdam, the
Netherlands). RA PBMC, used for microarray gene expression
profiles, were isolated from treatment-naïve early RA patients
included in the Rotterdam Early Arthritis Cohort Study. This
study was approved by the medical ethics committee of the
Erasmus MC Rotterdam. RA synovial fluid was isolated from
swollen knee joints of RA patients as part of usual care and
informed consent was given by all patients. Relevant clinical and
pharmaceutical patient information shown in Table S1.
Cell Sorting
PBMC were isolated using a Ficoll-gradient and stored in liquid
nitrogen until use. Frozen PBMC were thawed and stained with
monoclonal antibodies against CD45RO (clone UCHL1), CD4
(clone RPA-T4), CD127 (clone M21), CCR6 (clone 11A9) (all
BD Biosciences, San Diego, CA, USA), CD3 (clone UCHT1),
CCR6 (clone GO34E2), and CD25 (clone BC96) (all Biolegend,
San Diego, CA, USA) as appropriate in 0.5% BSA+ 2mM EDTA
in PBS. Dead cells (typically <5% of all cells) were excluded from
analysis by 4′6-Diamidino-2-Phenylindole Dilactate (DAPI).
For sorting CCR6+ Th memory cells and Tregs, PBMC
were pre-purified via automated magnetic-activated cell sorting
(autoMACS; Miltenyi Biotec, Leiden, The Netherlands) using
CD4 microbeads (Miltenyi Biotec) following manufacturer’s
instructions. Target cells were sorted on the FACSARIA III flow
cytometer (BD Biosciences) (Figure S1).
Cell Culture
Memory CCR6+ Th cells, excluding Tregs,
(CD4+CD45RO+CCR6+CD25low/int, Figure S1) were
cultured at a density of 1.25–2.5 × 104 cells/ml in Iscove’s
Modified Dulbecco’s Medium (IMDM) supplemented with 10%
fetal calf serum (FCS; Gibco, Waltham, MA, USA), 100 U/ml
penicillin/streptomycin, 2mM L-glutamine (all Lonza, Verviers,
Belgium), and 50µM β-mercaptoethanol (Sigma-Aldrich, St.
Louis, MO, USA). Cells were stimulated with soluble 0.3µg/ml
αCD3 and 0.4µg/ml αCD28 (Sanquin, Amsterdam, The
Netherlands) and cultured with 100 nM 1,25(OH)2D3 dissolved
in 100% ethanol (Leo Pharmaceutical Products, Ballerup,
Denmark) or with an equal volume of 100% ethanol (control
treatment). Final ethanol concentration in medium was 0.1%.
Suppression Assay
CD3+ cells (CD3+CD25low/intCD127+, Figure S1) were
sorted as responder cells and stained with 20µM Cell
Proliferation Dye eFluor450 following manufacturer’s protocol
(CPD; eBioscience Inc., San Diego, CA, USA). Autologous
Tregs (CD4+CD45RO+CD25hiCD127–, Figure S1) or cultured
memory CCR6+ Th cells (see Cell culture) were used as
putative suppressors and stained with 5µM carboxyfluorescein
succinimidyl ester (CFSE; LifeTechnologies, Eugene, OR, USA)
as described by others (33). In 96-well plates 2.5 × 104
responder cells were co-cultured with 2.5 × 104 suppressor
cells per well, under stimulation of 2.5 × 104 irradiated
autologous PBMC (40Gy, RS320, X-strahl, Surrey, UK) and
10µg/ml phytohemagglutinin P (PHA-P, Sigma-Aldrich). Where
indicated, 20% cell-free synovial fluid diluted in culture medium
was added. Proliferation was measured on the FACSCantoII Flow
Cytometer (BD Biosciences, San Diego, CA, USA) after 6 days.
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Chemotaxis Assay
4–5 × 104 cultured memory CCR6+ Th cells were seeded into
the upper chamber of 96-well transwell plates with a 3.0µm
pore polycarbonate membrane (Corning, New York, NY, USA)
in migration medium (T cell culture medium supplemented
with 0.5% BSA instead of 10% FCS). Migration medium
with or without 20% cell-free synovial fluid, 150 ng/ml CCL2,
1,000 ng/ml CCL20 or 150 ng/ml CXCL10 (all R&D Systems,
Minneapolis, MN, USA) was added to the lower chamber.
Each condition was run in duplicate or triplicate. After 3 h
incubation at 37◦C and 5% CO2, migrated cells were counted
using CountBright beads (Invitrogen, Waltham, MA, USA)
on a FACSCantoII Flow Cytometer. The migration index was
calculated by the number of cells that migrated in response to
chemokines or synovial fluid divided by the number of cells that
migrated to migration medium.
Flow Cytometry
For flow cytometry after culture, cells were stained in FACS buffer
(0.5% BSA + 0,05% NaN3 in PBS) with monoclonal antibodies
against CD4, CCR3, CXCR3, CCR2, CXCR4 (BioLegend), CCR6
(R&D Systems), CD45RO, CCR6, CCR7 (BD Biosciences), and
CXCR5 (eBioscience). Samples weremeasured on a FACSCantoII
Flow Cytometer.
Microarray
RNA was isolated from cells using the GenElute Mammalian
Total RNA Miniprep Kit (Sigma-Aldrich) following
manufacturer’s instructions. RNA purity was measured using
the 2100 Bioanalyzer Instrument (Agilent, Santa Clara, CA,
USA). For each sample 150 ng total RNA was amplified using
the Illumina TotalPrep RNA Amplification Kit (Ambion,
Invitrogen). Seven hundred fifty nanogram of amplified RNA
was hybridized following the Illumina protocol. Gene expression
profiles were generated using HumanHT-12 v4 BeadChip
human whole-genome expression arrays, which were scanned
using iScan (all Illumina, San Diego, CA, USA). Raw data were
background subtracted using Illumina GenomeStudio (V2010.1,
Illumina) and used for further analysis. The probe numbers
of genes discussed in this paper are listed in Table S2. The
microarray data are deposited in the GEO repository under
accession code GSE133426.
ELISA
Concentrations of IL-17A, IL-17F, IL-22, IFNγ, and IL-10 were
measured in culture supernatant using Ready-SET-Go! ELISA
(eBioscience) according to manufacturer’s instructions.
RT-PCR
RNA was isolated using the GenElute Mammalian Total RNA
Miniprep Kit (Sigma-Aldrich) following manufacturer’s
instructions. Isolated RNA was treated with 0.1 U/µl
DNAse (Invitrogen) and reverse transcribed into cDNA
using 10 U/µl Superscript II (Invitrogen) and random
hexamer primers. Primers were designed using ProbeFinder
Software and probes were selected from the Universal
Probe Library (Roche Applied Science, Indianapolis, IN,
USA) (Table S3). Real-time PCR was performed using
the Viia7 system (Applied Biosystems, Waltham, MA,
USA) and data were analyzed using QuantStudio Real-
Time PCR Software version 1.3 (Applied Biosystems).
Gene expression was normalized against hypoxanthine
phosphoribosyltransferase (HPRT).
Statistical Analysis
Paired Student’s T-test or ANOVA with a Bonferroni post-test
were used to test differences between two or more groups,
respectively. The analysis was performed using Prism software
version 6.01 (GraphPad Software, La Jolla, CA, USA).
RESULTS
1,25(OH)2D3 Inhibits the Th17 Phenotype
While Inducing a Regulatory Gene
Signature in Memory CCR6+ Th Cells
To study the potential conversion from a pro- to an anti-
inflammatory phenotype in memory CCR6+ Th cells, we
first studied their cytokine expression profiles after in vitro
1,25(OH)2D3 treatment. Previously, we have shown that
1,25(OH)2D3 already has inhibitory effects on Th17 cells from
a concentration of 0.1 nM, but that a dose of 100 nM has the
optimal suppressive effects on their pro-inflammatory phenotype
(22, 34). Therefore, memory CCR6+ Th cells, specifically
excluding Tregs since they can also express CCR6 (35), were
sorted from healthy controls and cultured with or without
100 nM 1,25(OH)2D3 for 3 days. In line with previous data
(18), we found that 1,25(OH)2D3 inhibited the pro-inflammatory
cytokines IL-17A, IL-22, and IFNγ. Interestingly, the anti-
inflammatory cytokine IL-10 was upregulated (Figure 1A).
This potential induction of an anti-inflammatory phenotype
was further studied via gene expression analyses for factors
important for the Th17 phenotype and pathogenicity (RORC,
IL23R), transcription factors characterizing Treg or Tr1 cells
(FOXP3, ITGA2, CD226, LAG3) (36, 37), genes required for
Tr1 development and IL-10 production (PRDM1, AHR, MAF)
(38–40) and factors important for the suppressive function of
Tregs and Tr1 cells (CTLA4, PDCD1, IL10RA, IL10RB) (41–43).
Although RORC and IL23R were not significantly modulated in
the memory CCR6+ Th cells from healthy controls, regulatory
genes such as FoxP3 and CTLA4 were induced in response to
1,25(OH)2D3 (Figure 1B). While MAF showed a trend toward
induction by 1,25(OH)2D3, it was only expressed in two out
of seven donors (data not shown). Of the other investigated
genes only IL10RB, PRDM1, and AHR were not modulated
by 1,25(OH)2D3, whereas PDCD1, encoding for the inhibitory
co-receptor PD1, was inhibited (Figure 1B).
These data show that 1,25(OH)2D3 induces an anti-
inflammatory signature in CCR6+ cells from healthy controls,
but this effect may not be similar in the more activated cells
from patients with an autoimmune disease such as rheumatoid
arthritis (RA) (7, 22). Therefore, memory CCR6+ Th cells
from treatment-naïve early RA patients were treated with or
without 1,25(OH)2D3 and used to generate microarray-based
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FIGURE 1 | 1,25(OH)2D3 treatment reduces pro-inflammatory gene expression in memory CCR6+ Th cells, while inducing an anti-inflammatory expression profile.
Memory CCR6+ Th cells were sorted from healthy controls (A,B) or treatment-naïve early RA patients (C) and cultured for 3 days with or without 1,25(OH)2D3.
Cytokine expression was measured using ELISA (A) and gene expression via RT-PCR (B) or microarray-based gene-expression profiles (C). In (C), fold change is
calculated by dividing the expression level after 1,25(OH)2D3 treatment by the level after control treatment. Pro-inflammatory genes are in normal font,
anti-inflammatory genes in bold font. FOXP3 and IL-17A were investigated but could not be detected by the probes on the microarray. Numbers behind genes
indicate different probes that were used to measure gene expression. Mean and SEM are given for 3 patients (C) or 7–8 healthy controls pooled from 2 independent
experiments (A,B), *p < 0.05, **p < 0.01.
gene expression profiles. Similar to our findings in healthy
cells, 1,25(OH)2D3 inhibited pro-inflammatory genes in the
memory CCR6+ Th cells from RA patients, except that in RA
cells also RORC and IL23R are inhibited (Figure 1C, normal
font). Interestingly, also in the RA cells the anti-inflammatory
genes were upregulated, again with the exception of PDCD1
(Figure 1C, bold font).
Altogether, these data suggest that 1,25(OH)2D3 inhibits the
pro-inflammatory phenotype of pathogenic memory CCR6+
Th cells, while inducing an anti-inflammatory phenotype in
these cells.
1,25(OH)2D3-Treated Memory CCR6+ Th
Cells Suppress Proliferation of CD3+
T Cells
The induction of genes such as IL-10 and CTLA4, which
are required for the suppressive function of regulatory T
cells, suggests that 1,25(OH)2D3-treated memory CCR6+ Th
cells could also have suppressive properties. Therefore, their
capacity to suppress proliferation of autologous CD3+ T
cells (excluding Tregs) was compared with the suppressive
potential of classical Tregs. In these suppression assays, control-
treated memory CCR6+ Th cells already slightly suppressed
Frontiers in Immunology | www.frontiersin.org 4 July 2019 | Volume 10 | Article 1504
Dankers et al. 1,25(OH)2D3-Induced Regulatory Capacity in Th17
proliferation of CD3+ T cells (Figure 2), a phenomenon that
has been described before when untreated cultured T cells
are used as suppressor cells (24). Importantly, 1,25(OH)2D3-
treatedmemory CCR6+ Th cells were equally potent suppressors
of CD3+ T cell proliferation as Tregs (Figure 2). This was
similar for the CD4+ cells and the CD4– cells within the
CD3+ T cells, demonstrating that both Th cells and cytotoxic
T cells, which are the main CD3+CD4– population, can
be suppressed by treated CCR6+ T helper memory cells
(Figure S2). These data show that the pro-inflammatory memory
CCR6+ Th cells acquire regulatory properties upon treatment
with 1,25(OH)2D3.
1,25(OH)2D3-Treated Memory CCR6+ Th
Cells Still Migrate Toward Inflammatory
Milieus in vitro
We next asked whether the 1,25(OH)2D3-treated memory
CCR6+ Th cells could contribute to the suppression of synovial
inflammation, for which the cells need to be able to migrate
toward inflammation. Therefore, the effect of 1,25(OH)2D3 on
the chemokine receptors expressed in treatment-naïve early
RA patients was first investigated using the microarray-based
gene expression profiles. The 1,25(OH)2D3-exposed memory
CCR6+ Th cells showed a shift in the chemokine receptor
profile, where some receptors are upregulated while others
are downregulated (Figure 3A). Importantly, the signature
chemokine receptor CCR6 is inhibited by 1,25(OH)2D3, while
other receptors such as CXCR3 and CCR2 are upregulated.
These data were verified on protein level using healthy memory
CCR6+ Th cells, where 1,25(OH)2D3 similarly modulates the
expression of all chemokine receptors except CCR4 (Figure 3B;
Figure S3). To investigate what these changes mean for the
actual migration of memory CCR6+ Th cells, both untreated
and 1,25(OH)2D3-treated memory CCR6+ Th cells were tested
for their migration toward CCL20, CXCL10, and CCL2. These
chemokines were selected because they are the ligands for
CCR6, CXCR3, and CCR2, respectively, which were the most
up- or downregulated chemokine receptors in both healthy
and RA cells. In a transwell chemotaxis assay, migration of
memory CCR6+ Th cells toward CCL20, the ligand for CCR6,
was significantly decreased after treatment with 1,25(OH)2D3
(Figure 4A). On the other hand, there was no difference in
the migratory capacity of the cells toward ligands for CXCR3
and CCR2, CXCL10, and CCL2 respectively, (Figure 4A). Since
single chemokines may not accurately represent the site of
inflammation, the migratory potential toward synovial fluid
obtained from RA patients was assessed as an example of
an inflammatory environment. Twenty percent synovial fluid
from these patients, all with a high disease activity (Table S1),
induced migration of both control-treated and 1,25(OH)2D3-
treated cells, although the latter migrated less efficiently in two
out of three patients (Figure 4B). This indicates 1,25(OH)2D3-
treated memory CCR6+ Th cells can still migrate toward
synovial fluid in vitro, although their migratory capacities may
be slightly altered.
1,25(OH)2D3-Treated Memory CCR6+ Th
Cells Are Equally Suppressive as Tregs in
Synovial Fluid
Although memory CCR6+ Th cells acquire a functional
regulatory phenotype and migrate toward sites of inflammation
upon exposure, they can only contribute to inhibiting synovial
inflammation if the local pro-inflammatory conditions do
not reverse the 1,25(OH)2D3-induced changes. Therefore,
the suppressive capacity of 1,25(OH)2D3-modulated memory
CCR6+ Th cells was assessed in the presence of 20% RA synovial
fluid using a similar assay as for Figure 2. Although T cell
proliferation was lower in synovial fluid than in medium (see
also Figure 2), 1,25(OH)2D3-treated memory CCR6+ Th cells
still suppressed T cell proliferation similar to Tregs under these
inflammatory conditions (Figure 5).
DISCUSSION
In this study, we demonstrated that human pro-inflammatory
IL-17A-producing memory CCR6+ Th cells acquire an anti-
inflammatory gene expression profile and regulatory properties
upon exposure to 1,25(OH)2D3. Importantly, these modulated
cells can still migrate toward synovial fluid and maintain their
suppressive capacity in this pro-inflammatory environment.
The 1,25(OH)2D3-mediated inhibition of the pro-
inflammatory gene signature in memory CCR6+ Th cells
is accompanied by induction of an anti-inflammatory gene
signature in both healthy controls and treatment-naïve early
RA patients. An exception to this pattern was the inhibition of
the suppressive co-receptor PD-1 by 1,25(OH)2D3. Although
not much research has been performed into the role of PD-1 in
RA, one case report suggests that PD-1 may be less important in
suppressing the autoimmune response than CTLA4. In this case,
a RA patient suffering from metastatic melanoma experienced
RA flares when treated with anti-CTLA4, but not when treated
with anti-PD-1 (44). Therefore, the inhibition of PD-1 by
1,25(OH)2D3 may also not be important for the regulatory
characteristics of modulated CCR6+ Th cells.
Although the pattern of genemodulation by 1,25(OH)2D3 was
largely similar between healthy controls and RA patients, there
were a few notable exceptions. Firstly, RORC and IL23R were
inhibited by 1,25(OH)2D3 in the cells from RA patients, but not
from healthy controls. Also, MAF was expressed in cells from
treatment-naïve early RA patients, but was hardly detectable
in healthy control cells. These differences could be due to the
higher activation state of the memory CCR6+ Th cells from RA
patients (7, 22). Furthermore, since vitamin D is considered to
be immunomodulatory rather than immunosuppressive (17), its
effects on highly activated RA cells may be stronger than on
healthy cells. The exact mechanism underlying the difference in
modulation between healthy cells and cells from RA and other
autoimmune diseases is of great interest for future research and
could provide insight into disease-specific pathogenesis.
In line with the expression of anti-inflammatory genes,
1,25(OH)2D3-treated memory CCR6+ Th cells suppress
proliferation of autologous T cells. This data corresponds with
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FIGURE 2 | Memory CCR6+ Th cells acquire regulatory capacities after treatment with 1,25(OH)2D3. Memory CCR6+ Th cells (without regulatory T cells) were
sorted from healthy controls and cultured for 3 days with or without 1,25(OH)2D3. Then they were co-cultured for 6 days with CPD-stained CD3+ T cells to assess
their suppressive potential. Target cell proliferation was assessed using flow cytometry, and sorted Treg cells were used as a positive control for suppression of
proliferation. (A) Representative plot of proliferation data. (B) Pooled proliferation data for 3 healthy donors. No suppr; no suppressors. Control-CCR6+;
control-treated memory CCR6+ Th cells. 1,25-CCR6+; 1,25(OH)2D3-treated memory CCR6+ Th cells. Mean and SEM are given and are representative of 4
independent experiments, **p < 0.01, ***p < 0.001, ****p < 0.0001.
the murine immune system, where IL-17A-producing cells
acquire Tr1-like properties during resolution of inflammation
(32). In human cells, an analog of 1,25(OH)2D3 induces a
regulatory phenotype in the total CD4+ population (Tregs
excluded) (45). Also, 1,25(OH)2D3 in combination with IL-2 can
promote this phenotypical change (24). However, both studies
still include naïve T cells, in which IL-10 production is also
induced upon 1,25(OH)2D3 treatment (46). Our study is the first
to demonstrate that regulatory properties can be induced in a
population of highly purified human pro-inflammatory memory
Th cells.
Despite the regulatory capacity of the 1,25(OH)2D3-treated
memory CCR6+ Th cells, the exact phenotype of these
cells remains to be determined. We verified protein surface
expression of important regulatory surface markers using flow
cytometry and found that the MFI of PD1, TIM3 and LAG3
were all significantly lower after exposure to 1,25(OH)2D3 in
contrast to CTLA4 and CD49B (data not shown). Further
characterization of the transcriptomic and proteomic changes
induced by 1,25(OH)2D3 in these cells is needed to further
identify the phenotype of these anti-inflammatory cells with
regulatory capacity.
For the conversion from a pro-inflammatory IL-17A-
producing memory CCR6+ Th cell to a regulating cell to be
functional in suppressing autoimmune diseases, the cells should
migrate toward the site of inflammation. 1,25(OH)2D3 treatment
modulates the chemokine receptor profile of memory CCR6+
Th cells, which alters their migration toward CCL20 but not
CXCL10 and CCL2. This is in line with previous studies, which
reported altered T cell migration toward various chemokines
after 1,25(OH)2D3 treatment (20, 45). The migration capacity
of 1,25(OH)2D3-treated memory CCR6+ Th cells toward RA
synovial fluid was unaffected or partially reduced, in a patient-
dependent manner. The differences between patients observed
in our study could be treatment-related, since for example
CCL2 is inhibited by TNFα treatment (47, 48), and CXCL9 and
CXCL10 decrease during treatment response (49). Furthermore,
the synovial fluid and memory CCR6+ Th cells were isolated
from allogeneic donors, which may play a role in our chemotaxis
assays. However, since the modulated memory CCR6+ Th cells
still migrated faster toward synovial fluid than to medium alone,
we concluded they still migrate toward the site of inflammation.
The modulated cells cannot only migrate to RA synovial fluid,
they also still suppress autologous T cell proliferation in this
environment. Notably, the baseline proliferation of T cells was
already inhibited in the presence of synovial fluid. This might be
due to the viscosity of the synovial fluid, which complicates the
cell-cell interaction that is required for stimulation by irradiated
PBMC. Inhibition of T cell proliferation has been shown before,
but only when more than 50% of the medium consisted of
synovial fluid and under stimulation that is not dependent on
cell-cell interaction (50). Nonetheless, the novel finding in this
study that 1,25(OH)2D3-treated memory CCR6+ Th cells retain
their suppressive capacity in synovial fluid suggests that these
cells may have therapeutic value in autoimmune diseases such
as RA.
It is tempting to consider transfer of autologous
1,25(OH)2D3-treated memory CCR6+ Th cells to promote
tolerance, similar to the 1,25(OH)2D3-treated dendritic cells
that are currently under clinical investigation (51). This could
be beneficial not only for RA, but also other Th17-driven
autoimmune diseases. For such a treatment to be effective,
the cells require a stable anti-inflammatory phenotype and
migratory capacity toward the site of inflammation. Importantly,
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FIGURE 3 | The chemokine receptor profile in memory CCR6+ Th shifts upon treatment with 1,25(OH)2D3. (A) Memory CCR6+ Th cells were sorted from
treatment-naïve early RA patients and cultured for 3 days with or without 1,25(OH)2D3. RNA was isolated and used for microarray analysis. Log2 of fold change
induced by 1,25(OH)2D3 treatment is shown for all chemokine receptors that were detected in the microarray data. (B) Changes in the chemokine receptor profile
were verified using flow cytometry on memory CCR6+ Th cells sorted from healthy controls which were cultured for 3 days with or without 1,25(OH)2D3. Mean and
SEM are given for 3 patients (A) or 5 healthy controls (B). MFI; mean fluorescent intensity, **p < 0.01, ***p < 0.001.
FIGURE 4 | 1,25(OH)2D3-treated memory CCR6+ Th cells still migrate toward an inflammatory environment. Memory CCR6+ Th cells were sorted from healthy
controls and cultured for 3 days with or without 1,25(OH)2D3. Their migratory capacity toward CCL20, CXCL10, CCL2 (A) or 20% synovial fluid from RA patients
(B) was assessed using a 3-µm pore transwell system. Mean and SEM are shown for 5 healthy controls from 2 independent experiments, *p < 0.05, ***p < 0.001.
the finding that modulated memory CCR6+ Th cells suppress
T cell proliferation not only upon restimulation with irradiated
PBMC and PHA, an inevitable consequence of the experimental
setup, but also in the presence of synovial fluid, indicates that
the anti-inflammatory phenotype might be stable. On the other
hand, RORC is still expressed in 1,25(OH)2D3-treated memory
CCR6+ Th cells in both healthy controls and RA patients,
suggesting that the cells did not completely transdifferentiate
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FIGURE 5 | The suppressive capacity of 1,25(OH)2D3-treated memory CCR6+ Th cells is retained in the presence of RA synovial fluid. Memory CCR6+ Th cells were
sorted from healthy controls and cultured for 3 days with or without 1,25(OH)2D3. They were then used in the same suppression assay as for Figure 3, but in the
presence of 20% synovial fluid. Proliferation for CD3+ T cells of six healthy donors (each depicted by its own symbol) is shown with or without suppressor cells, in the
presence of three different synovial fluid samples (upper panel). Overall proliferation in synovial fluid is calculated from the average proliferation of T cells from each
healthy donor in three different synovial fluids (lower panel). No suppr; no suppressors. Ctr-CCR6+; control-treated memory CCR6+ Th cells. 1,25-CCR6+;
1,25(OH)2D3-treated memory CCR6+ Th cells. Mean and SEM are shown for 6 healthy controls from 2 independent experiments. *p < 0.05.
into a classical Treg. Therefore, the extent of the phenotype
stability after 1,25(OH)2D3 exposure is of great clinical interest
for various autoimmune diseases. Both migration capacity and
therapeutic efficacy of 1,25(OH)2D3-treated memory CCR6+
Th cells should be further determined using transfer experiments
in autoimmune models.
Another issue that should be taken into account for the clinical
translation of these findings is the dose of 1,25(OH)2D3 used
in this study. Physiological steady-state levels are thought to be
around 0.1–0.2 nM (52, 53), whereas we used a higher dose of
100 nM. However, the level of 1,25(OH)2D3 might be higher
at the site of inflammation due to the capability of immune
cells to convert inactive vitamin D into the active 1,25(OH)2D3
metabolite (54, 55). Currently this issue remains unresolved and
direct supplementation of active 1,25(OH)2D3 is not possible
due to the possibility of severe side effects. Therefore, it will
be of great interest to understand the mechanism underlying
the shift in phenotype in response to 1,25(OH)2D3 as this
may provide us with new therapeutic targets. As a first step
to understanding the mechanism, the various subpopulations
within the memory CCR6+ Th cells should be investigated.
memory CCR6+ Th cells are a heterogeneous mixture of pro-
inflammatory cells, such as Th17, Th1/Th17 and Th17.1 cells,
but also unclassified cells that do not seem to belong to either
of these populations. All CCR6+ subpopulations express RORC
and varying levels of IL-17A, but they differ in chemokine
receptor expression, production of other cytokines such as
IFNγ and GM-CSF and transcription factor expression (e.g.,
Tbx21) (56). It is of great interest to investigate which of these
subpopulations is more prone to switch to an anti-inflammatory
cell with regulatory capacity, so certain cell types can be more
specifically targeted.
In this study it was demonstrated that committed
pro-inflammatory IL-17A-producing memory CCR6+
Th cells acquire regulatory properties upon treatment
with 1,25(OH)2D3. This process could normalize the
balance between pro- and anti-inflammatory mediators in
autoimmune diseases. These data provide a basis to further
explore the mechanisms to reset the pathogenic profile
of memory T cells during autoimmune inflammatory
diseases. This may lead to new developments to
activate resolution of inflammation in RA and other
autoimmune diseases.
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